Laertis Ikonomou, PhD
Co-Chair (August 2019-June 2020)
Boston University
Boston, MA, United States
[1] Ikonomou L, Wagner DE, Turner L, Weiss DJ. Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases. Ann Am Thorac Soc 2019;16:657-668. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201812-890CME
[2] Weiss DJ, Turner L, Levine AD, Ikonomou L. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions. Cytotherapy 2018;20:165-168. https://www.sciencedirect.com/science/article/pii/S1465324917307144
[3] Wagner DE, Turner L, Panoskaltsis-Mortari A, Weiss DJ, Ikonomou L. Co-opting of ClinicalTrials.gov by patient-funded studies. Lancet Resp Med 2018;6:579-581. https://www.sciencedirect.com/science/article/abs/pii/S221326001830242X
[4] Ikonomou L, Panoskaltsis-Mortari A, Wagner DE, Freishtat R, Weiss DJ. Unproven Stem Cell Treatments for Lung Disease-An Emerging Public Health Problem. Am J Respir Crit Care Med 2017;195:P13-P14. https://www.atsjournals.org/doi/10.1164/rccm.1957P13
[5] Ikonomou L, Freishtat RJ, Wagner DE, Panoskaltsis-Mortari A, Weiss DJ. The Global Emergence of Unregulated Stem Cell Treatments for Respiratory Diseases Professional Societies Need to Act. Ann Am Thorac Soc 2016;13:1205-1207. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201604-277ED
John Rasko, AO, MBBS, PhD, FRCPA, FRACP, FAHMS
Vice – Chair (June 2019-2020)
Royal Prince Alfred Hospital
Sydney, Australia
[1] Berger I, Ahmad A, Bansal A, Kapoor T, Sipp D, Rasko JEJ. Global Distribution of Businesses Marketing Stem Cell-Based Interventions. Cell Stem Cell 2016;19(2):158-162.
https://doi.org/10.1016/j.stem.2016.07.015
[2] Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, van Zimmeren E, Zarzeczny A, Rasko JEJ. Marketing of Unproven Stem Cell-Based Interventions: A Call to Action. Science Translational Medicine 2017;9(397). https://doi.org/10.1126/scitranslmed.aag0426
[3] Sipp D, McCabe C, Rasko JEJ. Show drugs work before selling them. Nature 2017;543:174-175. doi:10.1038/543174a
[4] Power C and Rasko JEJ. Promises and challenges of stem cell research for regenerative medicine. Annals of Internal Medicine 2011;155(10):706-U91. https://doi.org/10.7326/0003-4819-155-10-201111150-00010
[5] Rasko JEJ, O’Sullivan G, Ankeny R (2006). The ethics of inheritable genetic modification: a dividing line? Cambridge University Press.
Bruce Levine, PhD
University of Pennsylvania
Philadelphia, PA, United States
[1] Caplan A, Levine B. Hope, hype and help: ethically assessing the growing market in stem cell therapies. American Journal of Bioethics 2010; 10(5):24-5.
https://doi.org/10.1080/15265161.2010.481980
[2] Gunter KC, Caplan AL, Mason C, Salzman R, Janssen WE, Nichols K, Bouzas LF, Lanza F, Levine BL, Rasko JE, Shimosaka A, Horwitz E: Cell therapy medical tourism: time for action. Cytotherapy 2010; 12(8): 965-8. https://doi.org/10.3109/14653249.2010.532663
[3] Keeping patients safe from unproven cell therapies: an interview with the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies. RegMedNet February 2019. https://www.regmednet.com/channels/195-ethics-policy/posts/
Daniel J. Weiss, MD, PhD
Vice – Chair (June 2019-2020)
University of Vermont
Burlington, VT, United States
[1] Dominici M, Nichols K, Srivastava A, Weiss DJ, Eldridge P, Cuende N, Deans RJ, Rasko JE, Levine AD, Turner L, Griffin DL, O’Donnell L, Forte M, Mason C, Wagena E, Janssen W, Nordon R, Wall D, Ho HN, Ruiz MA, Wilton S, Horwitz EM, Gunter KC. 2013–2015 ISCT Presidential Task Force on Unproven Cellular Therapy. Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective. Cytotherapy 2015;17(12):1663-6. https://doi.org/10.1016/j.jcyt.2015.10.007
[2] Ikonomou L, Freishtat RJ, Wagner DE, Panoskaltsis-Mortari A, Weiss DJ. The Global Emergence of Unregulated Stem Cell Treatments for Respiratory Diseases. Professional Societies Need to Act. Ann Am Thorac Soc. 2016 Aug;13(8):1205-7. https://doi.org/10.1513/AnnalsATS.201604-277ED
[3] Weiss DJ, Rasko JE, Cuende N, Ruiz MA, Ho HN, Nordon R, Wilton S, Dominici M, Srivastava A. Part 2: Making the “unproven” “proven”. Cytotherapy 2016 Jan;18(1):120-3.
https://doi.org/10.1016/j.jcyt.2015.11.005
[4] Srivastava A, Mason C, Wagena E, Cuende N, Weiss DJ, Horwitz EM, Dominici M. Part 1: Defining unproven cellular therapies. Cytotherapy 2016 Jan;18(1):117-9.
https://doi.org/10.1016/j.jcyt.2015.11.004
[5] Ikonomou L, Panoskaltsis-Mortari A, Wagner DE, Freishtat RJ, Weiss DJ; American Thoracic Society Respiratory Cell and Molecular Biology Assembly Stem Cell Working Group. Unproven Stem Cell Treatments for Lung Disease-An Emerging Public Health Problem. Am J Respir Crit Care Med 2017;195(7):P13-P14. doi: 10.1164/rccm.1957P13. No abstract available. PMID: 28362195.
[6] Wagner DE, Turner L, Panoskaltsis-Mortari A, Weiss DJ, Ikonomou L. Co-opting of ClinicalTrials.gov by patient-funded studies. Lancet Respir Med. 2018; pii: S2213-2600(18)30242-X. doi: 10.1016/S2213-2600(18)30242-X
[7] Weiss DJ, Turner L, Levine AD, Ikonomou L. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions. Cytotherapy 2018;20(2):165-168. doi: 10.1016/j.jcyt.2017.10.002. Epub 2017 Nov 24. PMID:29239793.
[8] Ikonomou L, Wagner DE, Turner L, Weiss DJ. Translating Basic Research into Safe and Effective Cell-based Treatments for Respiratory Diseases. Ann Am Thorac Soc. 2019;16(6):657-668. doi: 10.1513/AnnalsATS.201812-890CME. PMID: 30917290.
[9] Ikonomou L and Weiss DJ. Turning the tide on unproven cell-based interventions. CHEST, in press 2019
Aaron Levine, PhD, MPhil
Vice – Chair (June 2019-2020)
Georgia Tech
Atlanta, GA, United States
[1] Imbach KJ, Patel A, and Levine AD. Ethical considerations in the translation of CAR-T cell therapies. Cell & Gene Therapy Insights 2018;4 (4): 295-307.
https://insights.bio/cell-and-gene-therapy-insights/journal/articles/ethical-considerations-in-the-translation-of-car-t-cell-therapies/
[2] Dodson BP and Levine AD. Challenges in the commercialization and translation of cell therapies. BMC Biotechnology 2015; 15:70.
https://bmcbiotechnol.biomedcentral.com/articles/10.1186/s12896-015-0190-4
[3] Levine AD and Wolf LE. The roles and responsibilities of physicians in patients’ decisions about unproven stem cell therapies. Journal of Law, Medicine & Ethics 2012;40(1) 122-34.
https://journals.sagepub.com/doi/10.1111/j.1748-720X.2012.00650.x
[4] Ryan KA, Sanders AN, Wang DD and Levine AD. Tracking the rise of stem cell tourism. Regenerative Medicine 2010;5(1): 27-33.
https://www.futuremedicine.com/doi/abs/10.2217/rme.09.70